It is tempting to speculate that a secondary effect of pharmacological STAT3 inhibition in cancer therapy may consist in a reduction of IL-15 dependent HIF-1α enrichment in NK cells, which may be expected to improve NK cell anti-tumor activity (12, 13). The gene discussed is STAT3; the disease is cancer.